Drug repurposing for antimicrobial discovery
- PMID: 30833727
- DOI: 10.1038/s41564-019-0357-1
Drug repurposing for antimicrobial discovery
Abstract
Antimicrobial resistance continues to be a public threat on a global scale. The ongoing need to develop new antimicrobial drugs that are effective against multi-drug-resistant pathogens has spurred the research community to invest in various drug discovery strategies, one of which is drug repurposing-the process of finding new uses for existing drugs. While still nascent in the antimicrobial field, the approach is gaining traction in both the public and private sector. While the approach has particular promise in fast-tracking compounds into clinical studies, it nevertheless has substantial obstacles to success. This Review covers the art of repurposing existing drugs for antimicrobial purposes. We discuss enabling screening platforms for antimicrobial discovery and present encouraging findings of novel antimicrobial therapeutic strategies. Also covered are general advantages of repurposing over de novo drug development and challenges of the strategy, including scientific, intellectual property and regulatory issues.
References
-
- O’Neill, J. Review on Antimicrobial Resistance: tackling a crisis for the health and wealth of nations (HM Government, 2014).
-
- Rossolini, G. M., Arena, F., Pecile, P. & Pollini, S. Update on the antibiotic resistance crisis. Curr. Opin. Pharmacol. 18, 56–60 (2014). - DOI
-
- Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50–55 (2014). - PubMed
-
- Kauffman, C. A., Pappas, P. G. & Patterson, T. F. Fungal infections associated with contaminated methylprednisolone injections. New Engl. J. Med. 368, 2495–2500 (2013). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
